Introduction 1 2 3 111 0 111 4 5 111 90 0 3 6 7 8 0 3 0 3 9 177 10 177 0 3 177 111 11 177 177 90 177 Materials and methods Patients 9 9 All patients gave written informed consent to participate in the study, which was approved by the medical ethical committee of the hospital. Methods 0 3 177 3 177 11 11 12 CT or MRI scanning was done within 3 months before the first therapy, and 6–8 weeks, 3 months and 6 months after the last treatment. In vivo measurements. Statistics  t  P Results 177 3 0 3 Nausea and vomiting within the first 24 h after the administration were present in 30% and 14% of the administrations, respectively, and were independent of the administered dose. Some abdominal pain was noticed during 11% of the administrations, especially in patients with liver metastases. Increased, mild hair loss was present in 17 of the 35 patients; hair regrowth had occurred at follow-up 3 and 6 months after the final administration. 9 9 4 1 1 2 Table 1. 177 Tumour type Response Total  CR PR SD PD  Carcinoid  4 (33%) 6 (50%) 2 (17%) 12 NE pancreas 1 (8%) 1 (8%) 7 (58%) 3 (25%) 12 NE unknown origin  4 (57%) 1 (14%) 2 (29%) 7 Gastrinoma  3 (100%)   3 Total 1 (3%) 12 (35%) 14 (41%) 7 (21%) 34 Fig. 1. A–C 177  A  B  C arrows  A  D, E D E arrows  D  E  Fig. 2.  A, B A 177 B arrow  A closed dots open dots C   P  P P P 3 Fig. 3.  Serum chromogranin-A concentrations during and after therapy in patients with PR, SD or PD. The reduction in the number of patients during the course of the follow-up was due to death or missing values. Note the logarithmic y-axis  n n 177 P Discussion 90 0 3 6 7 8 90 0 3 6 8 90 0 3 177 The patient-assessed global health score improved in 30% of patients during the treatment and the follow-up period. This is an important finding which reflects the improvement in patient well-being and stresses the scarcity of side-effects as perceived by patients. The fact that other scores mainly addressing symptoms did not change significantly is likely due to the diversity of symptoms between patients, the use of Sandostatin by symptomatic patients and the small size of the patient group. 177 177 177 90 177 13 14 90 177 15